Editas Medicine (EDIT) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Editas Medicine (EDIT) PT Lowered to $15 at Stifel
May 4, 2022 3:53 PM EDTStifel analyst Dae Gon Ha lowered the price target on Editas Medicine (NASDAQ: EDIT) to $15.00 (from $19.00) while maintaining a Hold rating.
The analyst commented, "No changes to our thesis pending clarity on the therapeutic profile of EDIT-101 (Leber congenital amaurosis type 10 [LCA10])... More
